专家：从单药治疗到多维联合，我国前列腺癌诊疗模式不断进展

Core Insights - The incidence and mortality rates of prostate cancer among men in China are rising, posing a significant public health issue [1] - The treatment paradigm for prostate cancer is evolving from single-agent therapies to combination therapies and precision medicine, supported by advancements in AI and talent development [1][3] Group 1: Current Situation and Challenges - Prostate cancer's five-year survival rate in China has increased to over 70%, but it still lags behind the over 95% rate in developed countries [2] - There is an urgent need to enhance public awareness and early screening for high-risk groups, including men over 50 and those with a family history [2] Group 2: Treatment Advances - Endocrine therapy remains the cornerstone of prostate cancer treatment, significantly delaying tumor growth and controlling disease progression [3] - The shift from surgical castration to medical castration has become mainstream due to equivalent clinical efficacy, with new androgen deprivation therapies emerging [2][3] Group 3: Future Directions - The challenge of treatment resistance in advanced prostate cancer is driving clinical research into new therapies, including AKT inhibitors, CAR-T cell therapy, and PSMA-targeted radiotherapy [4] - Ongoing development of tumor vaccines for prostate cancer indicates a proactive approach to treatment across different disease stages [4]